Zacks: Analysts Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to Announce -$0.41 Earnings Per Share

Equities research analysts predict that Seres Therapeutics, Inc. (NASDAQ:MCRB) will report earnings per share of ($0.41) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Seres Therapeutics’ earnings, with estimates ranging from ($0.44) to ($0.39). Seres Therapeutics posted earnings per share of ($0.28) during the same quarter last year, which would suggest a negative year over year growth rate of 46.4%. The business is scheduled to announce its next quarterly earnings report on Tuesday, July 27th.

On average, analysts expect that Seres Therapeutics will report full year earnings of ($1.57) per share for the current financial year, with EPS estimates ranging from ($1.83) to ($1.05). For the next year, analysts forecast that the business will post earnings of ($1.37) per share, with EPS estimates ranging from ($2.19) to ($0.12). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Tuesday, May 4th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.06). Seres Therapeutics had a negative return on equity of 2,867.98% and a negative net margin of 385.22%.

MCRB has been the subject of a number of analyst reports. Zacks Investment Research cut Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 25th. HC Wainwright upped their price target on Seres Therapeutics from $41.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, May 11th. Chardan Capital upgraded Seres Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $27.50 to $30.00 in a research note on Thursday, March 11th. Finally, Oppenheimer reiterated a “buy” rating and set a $38.00 price objective on shares of Seres Therapeutics in a research note on Tuesday, March 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Seres Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $34.14.

NASDAQ MCRB traded up $1.88 during trading hours on Tuesday, reaching $22.54. The company’s stock had a trading volume of 1,035,019 shares, compared to its average volume of 973,911. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -19.26 and a beta of 4.07. Seres Therapeutics has a 1-year low of $3.67 and a 1-year high of $38.50. The company has a debt-to-equity ratio of 0.13, a current ratio of 6.73 and a quick ratio of 6.73. The company’s 50-day moving average is $20.51 and its two-hundred day moving average is $24.46.

Several hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA grew its position in shares of Seres Therapeutics by 10.9% in the first quarter. BNP Paribas Arbitrage SA now owns 6,816 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 669 shares in the last quarter. Arizona State Retirement System grew its position in shares of Seres Therapeutics by 4.4% in the first quarter. Arizona State Retirement System now owns 18,594 shares of the biotechnology company’s stock valued at $383,000 after purchasing an additional 787 shares in the last quarter. Orion Capital Management LLC purchased a new stake in shares of Seres Therapeutics in the fourth quarter valued at approximately $25,000. Meeder Asset Management Inc. purchased a new stake in shares of Seres Therapeutics in the first quarter valued at approximately $26,000. Finally, Quantbot Technologies LP grew its position in shares of Seres Therapeutics by 162.5% in the first quarter. Quantbot Technologies LP now owns 2,100 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 1,300 shares in the last quarter. Institutional investors and hedge funds own 94.32% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).

Further Reading: Compound Annual Growth Rate (CAGR)

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.